A 12 week, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of TabetriTM on atopic dermatitis in children

utri Biotech0 个研究点目标入组 60 人开始时间: 待定最近更新: 2019年3月11日

适应症

试验速览

暂无简介。

•1) Patients who agree to participate in this experiment and write consent including the subject and the parent (or legal representative)
•2) Patients who aged 4~12 years of both sexes
•3) Patients who have had intermittent or persistent atopic dermatitis symptoms for more than 6 months
•4) Patients with mide to moderate atopic dermatitis symptoms (SCORing of Atopic Dermatitis, SCORAD index range from 20 to 50)

•1) Pateints who had severe skin disease, systemic disease
•2) Patients who had prior treatments associated with atopic dermatitis, including systemic antibiotics, corticosteroids, anti-histamines, immunosuppressant within 4 weeks prior to the study
•3) Patients who administered medicine, herbal medicine, any health functional supplements to improve atopic dermatitis within 1 week
•4) Patients who had phototherapy within 4 weeks prior to the study
•5) Patients who plan to participate in another human body test during this experiment
•6) Patients who participated in another human body test before this experiment within 4 weeks
•7) Patients who is deemed by the examiner to be inappropriate for this experiment

发起方

utri Biotech